These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9699888)

  • 21. Regulation of ovarian cholesterol metabolism: control of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase.
    Schuler LA; Toaff ME; Strauss JF
    Endocrinology; 1981 Apr; 108(4):1476-86. PubMed ID: 7472277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effect of monatepil maleate on acyl-CoA:cholesterol acyltransferase activity in the liver of cholesterol-fed Japanese monkeys.
    Sumiya T; Ikeno A; Kato H; Fujitani B; Masuda Y; Hosoki K; Miyazaki M
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):779-85. PubMed ID: 9234833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of an enriched-cholesterol diet on enzymatic cholesterol metabolism during rabbit gestation.
    Montoudis A; Boileau S; Simoneau L; Lafond J
    Life Sci; 2003 Aug; 73(11):1463-77. PubMed ID: 12850506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of correlation between ACAT mRNA expression and cholesterol esterification in primary liver cells.
    Rea TJ; DeMattos RB; Homan R; Newton RS; Pape ME
    Biochim Biophys Acta; 1996 Jan; 1299(1):67-74. PubMed ID: 8555254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall.
    Matsuo M; Ito F; Konto A; Aketa M; Tomoi M; Shimomura K
    Biochim Biophys Acta; 1995 Dec; 1259(3):254-60. PubMed ID: 8541332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
    Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
    Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase in rats.
    Lee SH; Park YB; Bae KH; Bok SH; Kwon YK; Lee ES; Choi MS
    Ann Nutr Metab; 1999; 43(3):173-80. PubMed ID: 10545673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-atherosclerotic effect of E5324, an inhibitor of acyl-CoA:cholesterol acyltransferase, in Watanabe heritable hyperlipidemic rabbits.
    Kogushi M; Tanaka H; Ohtsuka I; Yamada T; Kobayashi H; Saeki T; Takada M; Hiyoshi H; Yanagimachi M; Kimura T; Yoshitake S; Saito I
    Atherosclerosis; 1996 Aug; 124(2):203-10. PubMed ID: 8830933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.
    Asami Y; Yamagishi I; Murakami S; Araki H; Tsuchida K; Higuchi S
    Life Sci; 1998; 62(12):1055-63. PubMed ID: 9519807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterocyclic amides: inhibitors of acyl-CoA:cholesterol O-acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit.
    White AD; Purchase CF; Picard JA; Anderson MK; Mueller SB; Bocan TM; Bousley RF; Hamelehle KL; Krause BR; Lee P; Stanfield RL; Reindel JF
    J Med Chem; 1996 Sep; 39(20):3908-19. PubMed ID: 8831757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
    Parhofer KG; Barrett PH; Schwandt P
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
    Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T
    Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice.
    Johnston TP; Baker JC; Jamal AS; Hall D; Emeson EE; Palmer WK
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):831-42. PubMed ID: 10598127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
    Liang K; Vaziri ND
    Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits.
    Miyazaki A; Koieyama T; Shimada Y; Kikuchi T; Ito K; Kasanuki N; Koga T
    J Atheroscler Thromb; 2004; 11(1):22-8. PubMed ID: 15067195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.